Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Payables (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Payables readings, the most recent being $1.5 million for Q4 2025.

  • On a quarterly basis, Payables rose 106.69% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 106.69% increase, with the full-year FY2025 number at $1.5 million, up 106.69% from a year prior.
  • Payables hit $1.5 million in Q4 2025 for Arcadia Biosciences, down from $2.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.2 million in Q2 2021 to a low of $703000.0 in Q4 2024.
  • Median Payables over the past 5 years was $2.3 million (2023), compared with a mean of $2.5 million.
  • Biggest five-year swings in Payables: crashed 75.12% in 2022 and later skyrocketed 111.05% in 2023.
  • Arcadia Biosciences' Payables stood at $3.6 million in 2021, then crashed by 75.12% to $905000.0 in 2022, then soared by 111.05% to $1.9 million in 2023, then plummeted by 63.19% to $703000.0 in 2024, then surged by 106.69% to $1.5 million in 2025.
  • The last three reported values for Payables were $1.5 million (Q4 2025), $2.0 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.